Strengthening AMR Surveillance in Africa

By Crystal Lubbe

November 13, 2024

The article from Africa CDC titled “New Guidance Sets Path to Strengthen AMR Surveillance” focuses on the critical need to address the growing threat of Antimicrobial Resistance (AMR) in Africa. This guidance is essential given that AMR poses a significant public health threat, with more fatalities than HIV, TB, and malaria combined. The comprehensive approach outlined in this article presents key strategies for improving AMR surveillance in the region.

AMR as a Public Health Threat

Antimicrobial Resistance (AMR) has rapidly escalated into one of the leading threats to public health in Africa. It occurs when microorganisms become resistant to antimicrobial treatments, making infections harder to treat. This phenomenon not only increases disease transmission but also heightens illness severity and mortality rates.

New Guidance and Collaboration

The AMR Surveillance Guidance for the African Region was launched in September 2024, resulting from collaborative efforts between African countries, Africa CDC, the African Society for Laboratory Medicine (ASLM), the East, Central and Southern Africa Health Community (ECSA-HC), the West African Health Organization (WAHO), and the Fleming Fund. This guidance aligns national strategies with regional and global approaches to improve AMR surveillance.

One Health Approach

The guidance underscores a One Health approach, which integrates human, animal, plant, and environmental health to address AMR effectively. This holistic strategy aligns with the African Union AMR Landmark Report: Voicing African Priorities on the Active Pandemic.

Key Recommendations

The guidance recommends integrating AMR surveillance data into existing health information systems to enhance sustainability and efficiency. It also advises the establishment of National Central Coordinating Units (NCCUs) to oversee AMR surveillance activities. Furthermore, national and sub-national AMR steering committees are recommended to align national efforts with broader public health priorities.

Surveillance Challenges and Solutions

Conducting AMR surveillance in Africa faces considerable challenges, such as limited bacteriology services and inadequate laboratory infrastructure. To address these issues, the guidance suggests diverse surveillance sites, including both rural and urban healthcare facilities, to ensure the collection of representative data. Furthermore, it highlights the need for comprehensive data management systems to centralize information on patient demographics, clinical profiles, laboratory results, and antimicrobial use.

Quality Assurance and Capacity Building

The guidance emphasizes the importance of quality assurance measures, such as External Quality Assessment (EQA) programs, to maintain the accuracy of AMR surveillance data. It also highlights the necessity for capacity building, urging governments to invest in training healthcare workers and laboratory technicians on AMR testing and data management practices.

Overcoming Barriers

Despite facing barriers like limited funding and outdated data management systems, the guidance provides a roadmap for overcoming these challenges. Key focuses include improving governance, developing infrastructure, and building capacity. Partnerships with organizations like WHO, FAO, and WOAH are crucial for standardizing surveillance methods and facilitating data sharing.

Regional and International Support

Regional organizations such as ASLM and the Antimicrobial Resistance Surveillance Network (AMRSNET) are pivotal in supporting national surveillance efforts and promoting knowledge exchange. Initiatives like the international exchange program between Ethiopia and South Africa aim to share best practices for implementing effective AMR surveillance systems.

In summary, the new guidance is a vital step toward strengthening AMR surveillance in Africa, highlighting the need for collaboration, a One Health approach, and robust data management systems to tackle the significant public health threat posed by AMR. By focusing on quality assurance and capacity building, Africa can make substantial progress in the fight against Antimicrobial Resistance.

Reference url

Recent Posts

datopotamab deruxtecan approval
   

FDA Grants Datopotamab Deruxtecan Approval for HR-Positive Breast Cancer Treatment

đź’ˇ *What does the FDA’s latest approval mean for patients with advanced breast cancer?*
Datopotamab deruxtecan (Datroway) has just been approved for treating unresectable or metastatic HR-positive, HER2-negative breast cancer, offering new hope for patients who have already undergone multiple therapies. This breakthrough, stemming from the TROPION-Breast01 trial, showcases significant improvements in progression-free survival rates—a vital advancement in cancer care.

Curious about the implications of this treatment for both healthcare providers and patients? Dive into the full article to learn more!

#SyenzaNews #oncology #HealthcareInnovation

surrogate endpoints guidance
          

Surrogate Endpoints Guidance: New International Report Enhances HTA Practices

🔍 Are surrogate endpoints the key to shaping the future of health technology assessment?

A new report led by NICE reveals standardized guidance for using surrogate endpoints in health economic models, providing clarity and validation tools for HTA decisions. This collaborative effort across multiple global agencies aims to enhance predictions of long-term health benefits from short-term data.

Jump into the article to explore these impactful insights and learn how this guidance is set to improve health technology evaluations!

#SyenzaNews #HealthEconomics #HealthcareInnovation

cervical cancer prevention
    

Cervical Cancer Prevention Strategies: Insights from South African

🌍 Did you know South African women living with HIV face a significantly higher risk of cervical cancer?

Our latest article looks into the perspectives of women and their partners regarding innovative cervical cancer prevention strategies, including the acceptability of the intravaginal 5-fluorouracil (5FU) treatment. It highlights the critical role of education and counseling in improving screening uptake and treatment adherence.

Explore how we can enhance cervical health for vulnerable populations!

#SyenzaNews #globalhealth #oncology #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.